Biogen Phase 2 felzartamab trial in Graves' disease recruiting since July 2026
Biogen's GRAVITATE study testing felzartamab against placebo in Graves' disease is recruiting, with 60 participants targeted and primary completion estimated for early 2028.
This week's item covers a single Biogen study now underway in Graves' disease.
- Biogen's Phase 2 "GRAVITATE" trial (NCT07722546) is recruiting participants with Graves' disease, with an actual start date of 2026-07-30 and last update posted 2026-09-04. The trial is a placebo-controlled, multicenter, randomized Phase 2 study evaluating felzartamab compared to placebo in adult participants with Graves' Disease.1 The study plans to enroll 60 participants and its primary outcome is how many participants have normal thyroid levels without receiving any ATD medicine at Week 241, with estimated primary completion on 2028-01-31.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.